Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: A quantitative analysis of HIF-1

Archives of Gynecology and Obstetrics

Volumn 279, Issue 6, 2009, Pages 789-796

  Miyazawa, Masaki ^a   Yasuda, Masanori ^b   Fujita, Mariko ^a   Hirasawa, Takeshi ^a   Kajiwara, Hiroshi ^a   Hirabayashi, Kenichi ^a   Ogane, Naoki ^c   Shimizu, Michio ^b   Asanuma, Hideki ^a   Murakami, Masaru ^a   Takekoshi, Susumu ^a   Mikami, Mikio ^a   Osamura, R Yoshiyuki ^a  

^a TOKAI UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

DNA binding HIF 1 activity; HIF 1 ; Ovary

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BINDING ASSAY; BIOACCUMULATION; CANCER CHEMOTHERAPY; CELL HYPOXIA; CELL NUCLEUS; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; ENDOMETRIOID ADENOCARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUCINOUS CARCINOMA; OVARY ADENOCARCINOMA; OVARY CLEAR CELL ADENOCARCINOMA; OVARY MUCINOUS ADENOCARCINOMA; OVARY MUCINOUS ADENOMA; OVARY MUCINOUS BORDERLINE TUMOR; OVARY SEROUS ADENOCARCINOMA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SCHOOL CHILD; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANOXIA; CELL NUCLEUS; CHILD; CYTOPLASM; DNA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; YOUNG ADULT;

EID: 67349198732     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-008-0816-z     Document Type: Article

References (35)

1. H Jiang Y Feng 2006 Hypoxia-inducible factor 1α (HIF-1α) correlated with tumor growth and apoptosis in ovarian cancer Int J Gynecol Cancer 16 405 412 10.1111/j.1525-1438.2006.00310.x
2. DE Richard E Berra J Pouyssegur 1999 Angiogenesis: how a tumor adapts to hypoxia Biochem Biophys Res Commun 266 718 722 10.1006/bbrc.1999.1889 (Pubitemid 30042496)
3. 2 tension Am J Physiol 271 C1172 C1180 (Pubitemid 126757715)
4. AC Epstein JM Gleadle LA McNeill KS Hewitson J O'Rourke DR Mole 2001 C. elegan EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation Cell 107 43 54 10.1016/S0092-8674(01)00507- 4 (Pubitemid 32972036)
5. GL Semenza 2002 HIF-1 and tumor progression: pathophysiology and therapeutics Trends Mol Med 8 S62 S67 10.1016/S1471-4914(02)02317-1 (Pubitemid 34297081)
6. M Yasuda M Shimizu M Fujita M Miyazawa X Tang H Kajiwara 2007 Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy Cancer Detect Prev 31 396 401 10.1016/j.cdp.2007.10.007 (Pubitemid 350166793)
7. A Mayer M Höckel P Vaupel 2006 Endogenous hypoxia markers in locally advanced cancers of the uterine cervix: reality or wishful thinking? Strahlenther Onkol 182 501 510 10.1007/s00066-006-1525-9 (Pubitemid 44316238)
8. E Sivridis A Giatromanolaki KC Gatter AL Harris MI Koukourakis Tumor and Angiogenesis Research Group 2002 Association of hypoxia-inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma Cancer 95 1055 1063 10.1002/cncr.10774
9. P Birner M Schindl A Obermair G Breitenecker G Oberhuber 2001 Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy Clin Cancer Res 7 1661 1668 (Pubitemid 32708633)
10. R Osada A Horiuchi N Kikuchi J Yoshida A Hayashi M Ota Y Katsuyama G Melillo I Konishi 2007 Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma Hum Pathol 38 1310 1320 10.1016/j.humpath.2007.02.010 (Pubitemid 47247486)
11. Miyazawa M, Yasuda M, Kaziwara H, Iida T, Fujita M, Hayashi M, et al. (2005) Expression of hypoxia-related markers, GLUT-1 and HIF-1 alpha, in the ovarian tumors: Association with histology and tumor grade. Acta His Chem 38:abstr S26
12. M Yasuda M Miyazawa M Fujita H Kajiwara T Iida T Hirasawa 2008 Expression of hypoxia inducible factor-1• (HIF-1α) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character Oncol Rep 19 111 116
13. T Iida M Yasuda M Miyazawa M Fujita RY Osamura T Hirasawa T Muramatsu M Murakami K Saito M Mikami 2008 Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1 alpha/GLUT-1 expression Arch Gynecol Obstet 277 539 546 10.1007/s00404-007-0500-8
14. T Sugiyama T Kamura J Kigawa N Terakawa Y Kikuchi T Kita 2000 Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy Cancer 88 2584 2589 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5 (Pubitemid 30331967)
15. H Itamochi J Kigawa T Sugiyama Y Kikuchi M Suzuki N Terakawa 2002 Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary Obstet Gynecol 100 281 287 10.1016/S0029-7844(02)02040-9
16. H Itamochi J Kigawa R Akeshima S Sato S Kamazawa M Takahashi 2002 Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary Oncology 62 349 353 10.1159/000065067
17. CM Ho YJ Huang TC Chen SH Huang FS Liu CC Chang Chien 2004 Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease Gynecol Oncol 94 197 203 10.1016/j.ygyno.2004.04.004 (Pubitemid 38950520)
18. H Jiang Y Feng 2006 Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer Int J Gynecol Cancer 16 Suppl 1 405 412 10.1111/j.1525-1438.2006.00310.x
19. DA Guertin DM Sabatini 2005 An expanding role for mTOR in cancer Trends Mol Med 11 353 361 10.1016/j.molmed.2005.06.007 (Pubitemid 41080576)
20. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 10.1038/nrc1362 (Pubitemid 38579480)
21. CC Hudson M Liu GG Chiang DM Otterness DC Loomis F Kaper 2002 Regulation of hypoxia-inducible factor 1 alpha expression and function by the mammalian target of rapamycin Mol Cell Biol 22 7004 7014 10.1128/MCB.22.20.7004-7014.2002
22. KS Kimbro JW Simons 2006 Hypoxia-inducible factor-1 in human breast and prostate cancer Endocr Relat Cancer 13 739 749 10.1677/erc.1.00728
23. HM Sowter RR Raval JW Moore PJ Ratcliffe AL Harris 2003 Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia Cancer Res 63 6130 6134 (Pubitemid 37255150)
24. T Klatte DB Seligson SB Riggs JT Leppert MK Berkman MD Kleid 2007 Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma Clin Cancer Res 13 7388 7393 10.1158/1078-0432.CCR-07-0411
25. S Mabuchi DA Altomare DC Connolly A Klein-Szanto S Litwin MK Hoelzle 2007 RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer Cancer Res 67 2408 2413 10.1158/0008-5472.CAN-06-4490 (Pubitemid 46548923)
26. M Fujita M Yasuda K Kitatani M Miyazawa K Hirabayashi 2007 An up-to-date anti-cancer treatment strategy focusing on HIF-1alpha suppression: its application for refractory ovarian cancer Acta Histochem Cytochem 40 139 142 10.1267/ahc.07024
27. EJ Yeo YS Chun JW Park 2004 New anticancer strategies targeting HIF-1 Biochem Pharmacol 68 1061 1069 10.1016/j.bcp.2004.02.040 (Pubitemid 39094271)
28. S Lee EI Garner WR Welch RS Berkowitz SC Mok 2007 Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma Gynecol Oncol 106 311 317 10.1016/j.ygyno.2007.03.041 (Pubitemid 47087928)
29. DT Dang SY Chun K Burkitt M Abe S Chen P Havre 2008 Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition Cancer Res 68 1872 1880 10.1158/0008-5472.CAN-07-1589
30. Y Takahashi M Nishikawa Y Takakura 2008 Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1alpha expression in tumor cells and hepatocytes Gene Ther 15 572 582 10.1038/sj.gt.3303103
31. P Amornphimoltham V Patel K Leelahavanichkul RT Abraham JS Gutkind 2008 A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer Cancer Res 68 1144 1153 10.1158/0008-5472.CAN-07-1756
32. HY Jiang YJ Feng 2004 Inhibition of hypoxia-inducible factor 1alpha expression and tumor growth in SKOV3 ovarian cancer model by sirolimus Zhonghua Fu Chan Ke Za Zhi 39 474 477
33. MB Atkins M Hidalgo WM Stadler TF Logan JP Dutcher GR Hudes 2004 Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma J Clin Oncol 22 909 918 10.1200/JCO.2004.08.185 (Pubitemid 41103603)
34. JA Sosman I Puzanov MB Atkins 2007 Opportunities and obstacles to combination targeted therapy in renal cell cancer Clin Cancer Res 13 764s 769s 10.1158/1078-0432.CCR-06-1975 (Pubitemid 46220112)
35. S Mabuchi DA Altomare M Cheung L Zhang PI Poulikakos HH Hensley 2007 RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model Clin Cancer Res 13 4261 4270 10.1158/1078-0432.CCR-06-2770